Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Eterna Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ERNA
Nasdaq
8731
https://eternatx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Eterna Therapeutics Inc
Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights
- Mar 20th, 2023 8:10 pm
Insiders might want to re-evaluate their US$2.7m stock purchase as Eterna Therapeutics Inc. (NASDAQ:ERNA) drops to US$16m
- Mar 16th, 2023 11:04 am
EXCLUSIVE: Lineage Cell Inks Exclusive Agreement For Novel Cell-Based Therapies With Potential In Neurology
- Feb 22nd, 2023 2:46 pm
Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications
- Feb 22nd, 2023 1:00 pm
Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President
- Jan 4th, 2023 1:30 pm
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Dr. Matt Angel, CEO Eterna Therapeutics
- Dec 20th, 2022 1:05 pm
Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies
- Nov 1st, 2022 12:30 pm
Eterna Therapeutics to Present at iPSC-Derived Immunotherapies Congress
- Oct 18th, 2022 12:30 pm
Eterna Therapeutics Completes Name Change, Acquires Option to License iPSC-Derived NK and T Cell Therapies from Exacis Biotherapeutics
- Oct 17th, 2022 12:30 pm
Scroll